ARKG - Where Will ARK Genomic Revolution ETF Be in 5 Years?
Cathie Wood and her ARK Investment Management firm focus on areas of disruptive innovation. And few sectors have the potential to be more disruptive than genomics, where recent advancements are set to transform the healthcare industry. Technology improvements and cost reductions in genetic testing and therapies are making it possible to diagnose, treat, and even cure devastating diseases.
ARK management believes these advancements are ushering in a "Genomic Age" that could create trillions of dollars in equity market capitalization by 2024.
To take advantage of these trends, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) invests in companies proving to be "leaders, enablers, and beneficiaries" of CRISPR (a gene-editing technique) , targeted therapeutics, bioinformatics, molecular diagnostics, stem cells, agricultural biology, and healthcare innovation.
For further details see:
Where Will ARK Genomic Revolution ETF Be in 5 Years?